Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
January 2018 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the January BNF eNewsletter.
Four new drug monographs have been added to the BNF in the last month, including - cenegermin, ribociclib, telotristat ethyl, and sofosbuvir with velpatasvir and voxilaprevir.

This issue contains dose changes for anastrozole, raloxifene, and tamoxifen when used for chemoprevention of breast cancer in women at moderate-to-high risk [unlicensed use] and for fluoxetine, gabapentin, paroxetine, and venlafaxine when used for menopausal symptoms, particularly hot flushes, in women with breast cancer [unlicensed use]. The guidance on the management of acute porphyrias and Parkinson's disease have both been updated. We have included updated MHRA advice on quinine: reminder of dose-dependent QT-prolonging effects. You will also find NICE technology appraisals including tofacitinib for moderate-to-severe rheumatoid arthritis and reslizumab for treating severe eosinophilic asthma.

This month take a look at our BNF case study on chemoprevention of familial breast cancer.
Kind regards,
BNF Team
I In this issue
Coming Soon More >  
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
I Coming Soon! BNF & BNFC available on the NEW MedicinesComplete
The Royal Pharmaceutical Society is launching a NEW MedicinesComplete experience helping you to quickly and easily discover content to make rapid, well informed decisions. These changes have been driven by your needs and we are delighted to introduce you to the BNF on the new MedicinesComplete.

MedicinesComplete
The most notable changes include the ability to browse drug groupings by therapeutic areas, along with enhancements to search, design and layout of content - helping you navigate to the most relevant content.

To take advantage of the improvements, you will need to re-register your details and confirm your eligibility to receive continued NHS access. We will be providing you with information on how to do this so look out for further emails with instructions.

Please visit www.new.medicinescomplete.com for more information on changes and FAQ's.
I Significant
changes
This month's changes to the clinical content of these publications are described in two parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNF 74 - BNFC 2017-2018
BNF BNF for Children Update
Acute porphyrias: updated guidance on management
For further information, see acute porphyrias.
Non-medical prescribing: updated guidance
For further information, see non-medical prescribing.
Controlled drugs and drug dependence: updated guidance
For further information, see controlled drugs and drug dependence.
Quinine: reminder of dose-dependent QT-prolonging effects (MHRA advice)
For further information, see quinine.
Gentamicin: potential for histamine-related adverse drug reactions with some batches (MHRA advice)
For further information, see gentamicin.
Dose changes
Naloxone hydrochloride [clarification of maximum initial dose in children aged 1 month - 11 years for overdosage with opioids]]
For further information, see naloxone.
BNF Update
Cenegermin: new drug monograph
For further information, see cenegermin.
Ribociclib: new drug monograph
For further information, see ribociclib.
Parkinson's disease: updated guidance on management
For further information, see Parkinson's disease.
Dose changes
Tamoxifen: Breast cancer [chemoprevention in women at moderate-to-high risk] [unlicensed use]
For further information, see tamoxifen.
Fluoxetine: Menopausal symptoms, particularly hot flushes, in women with breast cancer (except those taking tamoxifen) [unlicensed use]
For further information, see fluoxetine.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Reslizumab for treating severe eosinophilic asthma
Tofacitinib for moderate-to-severe rheumatoid arthritis
Other changes
To review other changes in the BNF, click on changes.
I News
Reminder - help from CPPE with BNF 74
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 74. It comprises 10 practical case studies, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the September 2017 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2018 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2018 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.